Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus

(2019) Xueting Yao et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma

(2019) Sagar Lonial et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria

(2018) Arjun Lakshman et al.   Blood Cancer Journal

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

(2017) S K Kumar et al.   LEUKEMIA

Smoldering multiple myeloma

(2015) S. V. Rajkumar et al.   BLOOD

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Teriflunomide (Leflunomide) Promotes Cytostatic, Antioxidant, and Apoptotic Effects in Transformed Prostate Epithelial Cells: Evidence Supporting a Role for Teriflunomide in Prostate Cancer Chemoprevention

(2015) Numsen Hail et al.   NEOPLASIA

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

(2014) P. G. Richardson et al.   BLOOD

Recent improvement in survival of patients with multiple myeloma: variation by ethnicity

(2013) Dianne Pulte et al.   LEUKEMIA & LYMPHOMA

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

(2013) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis

(2012) Catherine O’Doherty et al.   PHARMACOGENOMICS

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

(2011) J. A. Zonder et al.   BLOOD

Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells

(2011) S. Dietrich et al.   CLINICAL CANCER RESEARCH

DHODH modulates transcriptional elongation in the neural crest and melanoma

(2011) Richard Mark White et al.   NATURE

Chromatographic separation and sensitive determination of teriflunomide, an active metabolite of leflunomide in human plasma by liquid chromatography-tandem mass spectrometry

(2010) Jignesh M. Parekh et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

(2009) E Kastritis et al.   LEUKEMIA

Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells

(2009) P. Baumann et al.   MOLECULAR CANCER THERAPEUTICS

The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide

(2009) Andrzej Pawlik et al.   PHARMACOGENOMICS

Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients

(2008) Petra Bohanec Grabar et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design

(2008) Jeffrey M. Skolnik et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

(2007) A. Dispenzieri et al.   BLOOD